Policy | November 11, 2025
Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The offering is expected to close on November 10, 2025, subject to customary closing conditions
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
Move to increase affordability and accessibility for heart failure patients across the country
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
